hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06376084 id: D5161R00055 briefTitle: Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC acronym: FOREFRONT overallStatus: NOT_YET_RECRUITING date: 2024-07-24 date: 2028-02-28 date: 2028-02-28 date: 2024-04-19 date: 2024-04-19 name: AstraZeneca class: INDUSTRY briefSummary: To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS. conditions: Carcinoma, Non-Small-Cell Lung conditions: Lung Neoplasms conditions: Respiratory Tract Neoplasms conditions: Thoracic Neoplasms conditions: Neoplasms by Site conditions: Neoplasms conditions: Lung Diseases conditions: Respiratory Tract Diseases conditions: Carcinoma, Bronchogenic conditions: Bronchial Neoplasms studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 700 type: ESTIMATED measure: Real-World Progression Free Survival (rwPFS) measure: Chemotherapy regimen measure: Duration of chemotherapy (induction and maintenance cycles) measure: Response rate measure: Duration of response measure: Overall survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Chest Hospital city: Shanghai state: Shanghai zip: 200030 country: China name: Rong LI role: CONTACT phone: +8621-22200000-5451 email: lrw@hotmail.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06376071 id: fungal rhinosiusitis briefTitle: Sinonasal Risk Factors for Occurrence of Unilateral Versus Bilateral Allergic Fungal Rhinosinusitis . overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-06-30 date: 2024-04-19 date: 2024-04-19 name: Assiut University class: OTHER briefSummary: This study aims to assess Sinonasal risk factors for occurrence of unilateral versus bilateral allergic fungal rhino sinusitis regarding::
2. other associated factors like demographic ,environmental, immunological and climatic risk factors . conditions: Allergic Fungal Rhinosinusitis studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: CROSS_SECTIONAL count: 76 type: ESTIMATED name: functional endoscopic sinus surgery measure: Sinonasal risk factors for occurrence of unilateral versus bilateral allergic fungal rhinosinusitis sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376058 id: 434/06-06-2022 briefTitle: Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section acronym: annie-mariana overallStatus: RECRUITING date: 2024-01-10 date: 2026-01-10 date: 2026-01-10 date: 2024-04-19 date: 2024-04-19 name: Aretaieion University Hospital class: OTHER briefSummary: This will be a prospective randomized study, aiming at comparing an intrathecal fixed dose of chloroprocaine 1% versus an intrathecal fixed dose of ropivacaine 0.75% in elective cesarean sections conditions: Cesarean Section conditions: Local Anesthetic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Chloroprocaine 1% Injectable Solution name: Ropivacaine 0.75% Injectable Solution measure: Time from spinal anesthesia to T10 block (min) measure: Time from spinal anesthesia to T4 block (min) measure: Time of spinal anesthesia to Bromage =3 measure: level of sensory block every 3 min measure: level of sensory block every 15 min measure: highest level of sensory block measure: time from spinal anesthesia to highest level of sensory block measure: duration of sensory block measure: pain at surgical incision measure: pain at neonatal delivery measure: pain at peritoneal manipulation measure: pain at Post Anesthesia Care Unit (PACU) admission measure: pain at Post Anesthesia Care Unit (PACU) discharge measure: need for rescue analgesia intraoperatively measure: Bromage scale every 3 min after spinal anesthesia measure: Bromage scale every 15 min measure: duration of motor block measure: duration of staying in PACU measure: Neonatal Apgar score at 1 minute measure: Neonatal Apgar score at 5 minutes measure: neonatal blood gases measure: incidence of neonatal acidosis measure: incidence of hypotension measure: incidence of bradycardia measure: need for vasoconstrictor measure: need for atropine measure: incidence of nausea/vomiting measure: incidence of dizziness measure: incidence of drowsiness measure: incidence of discomfort measure: incidence of shivering measure: need for rescue analgesia in PACU measure: time from spinal anesthesia to rescue analgesia in PACU measure: incidence of neurological symptoms during hospital stay measure: incidence of neurological symptoms 2 months after the operation measure: incidence of low back pain measure: time from spinal anesthesia to mobilization measure: mother's satisfaction from anesthesia measure: gynecologist's satisfaction sex: FEMALE minimumAge: 18 Years maximumAge: 48 Years stdAges: ADULT facility: Aretaieion University Hospital status: RECRUITING city: Athens zip: 11528 country: Greece name: Kassiani Theodoraki, PhD, DESA role: CONTACT phone: 6974634162 email: ktheodoraki@hotmail.com name: Marianna Mavromati, MD role: CONTACT email: marimavr14@gmail.com lat: 37.97945 lon: 23.71622 hasResults: False
nctId: NCT06376045 id: 20220093 briefTitle: A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2026-08-10 date: 2026-10-02 date: 2024-04-19 date: 2024-04-19 name: Amgen class: INDUSTRY briefSummary: The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations. conditions: Asthma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 428 type: ESTIMATED name: Rocatinlimab name: Placebo measure: Annualized Asthma Exacerbation Rate (AAER) During the Blinded Treatment Period measure: Change From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV1) measure: Annualized Rate of Composite Endpoint for Exacerbations (CompEx) Events During the Blinded Treatment Period measure: Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 48 measure: Change From Baseline in Pre-BD FEV1 measure: Change From Baseline in Asthma Symptom Diary (ASD) Score measure: Number of Participant Achieving ACQ-6 Response at Week 48 measure: Change From Baseline in ACQ-6 measure: Change From Baseline in Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ (S)) Self-Administered Score measure: Number of Participants Achieving AQLQ (S) Response at Week 48 measure: Annualized Rate of Asthma Exacerbation Leading to Hospitalization or Emergency Room Visits During the Blinded Treatment Period measure: Time to First Asthma Exacerbation Event measure: Time to First CompEx Event measure: Number of Participants with a CompEx Event During the Double Blinded Treatment Period measure: Annualized Rate of CompEx Events measure: Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Levels measure: Serum Rocatinlimab Concentrations measure: Trough Concentration (Ctrough) of Rocatinlimab measure: Number of Participants with Treatment-emergent Adverse Events measure: Number of Participants with Serious Adverse Events measure: Number of Participants with Anti-rocatinlimab Antibody Formation sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376032 id: Akili-068 briefTitle: EndeavorOTC® Research Study in College Students overallStatus: RECRUITING date: 2024-01-10 date: 2025-12-31 date: 2025-12-31 date: 2024-04-19 date: 2024-04-23 name: Akili Interactive Labs, Inc. class: INDUSTRY name: Landmark College name: Villa Maria College briefSummary: The objective of this study is to evaluate the impact of a digital therapeutic (EndeavorOTC®, also known as AKL-T01A) on clinical symptoms of executive and cognitive functioning in a real-world sample of university students. This study aims to answer whether EndeavorOTC represents a useful intervention for targeting broad cognitive and emotional health among university students. conditions: Attention conditions: Cognition conditions: University Students studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Eligible students will be randomized\* to two cohorts: the first will receive immediate access to AKL-T01, and the second will complete weekly online surveys and receive access to AKL-T01 after the first group has completed the recommended 6 weeks of use. Regardless of group assignment, all participants will receive full 12-weeks of access to AKL-T01 during the course of the study.
\*Depending on enrollment numbers for a given semester (e.g., if \<100 students are enrolled and the study is underpowered to conduct between-group comparisons), all participants may be assigned to receive treatment immediately (i.e., single-arm design) and primary study hypotheses may be evaluated according to within-person changes in outcomes. primaryPurpose: OTHER masking: NONE count: 500 type: ESTIMATED name: EndeavorOTC® measure: Computerized Adaptive Test, Mental Health (CAT-MH®) measure: PROMIS Cognitive Function v2.0 - Short Form measure: PROMIS Satisfaction with Participation in Discretionary Social Activities (v1.0) measure: General Academic Self-Efficacy scale (GASE) measure: Mental Health Quality of Life Scale (MHQoL) measure: Adult ADHD Self-Report Scale (ASRS) measure: Patient Health Questionnaire-4 (PHQ-4) measure: System Usability Scale (SUS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Villa Maria College status: RECRUITING city: Cheektowaga state: New York zip: 14225 country: United States name: Laura Pietak role: CONTACT phone: 716-961-2869 email: lpietak@villa.edu lat: 42.90339 lon: -78.75475 facility: Landmark College status: RECRUITING city: Putney state: Vermont zip: 05346 country: United States name: Rick Bryck, PhD role: CONTACT phone: 802-387-6306 email: rickbryck@landmark.edu lat: 42.9748 lon: -72.52176 hasResults: False
nctId: NCT06376019 id: FDASU-RecID11352 briefTitle: Occlusion and Disocclusion Time in Immediately Loaded Overdentures Supported by Two Splinted Versus Non Splinted Interforaminal Implants overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2024-08-15 date: 2024-09-15 date: 2024-04-19 date: 2024-04-19 name: Ain Shams University class: OTHER briefSummary: complete denture wearers struggle to eat well with their dentures due to poor denture retention, stability, and occlusal disharmony. So, the current study protocol aims to compare the occlusion/ disocclusion time in immediately loaded implant retained overdentures supported by two interforaminal implants; splinted versus non splinted dental implants compared to the conventional complete denture. conditions: Edentulous Jaw studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: parallel assignment of the participants in ratio 1:1:1 will take place. For allocation concealment, opaque sealed envelopes will be used. primaryPurpose: TREATMENT masking: NONE maskingDescription: the statistician will be the only one to be blinded count: 27 type: ESTIMATED name: solitary Implant loading with ball attachment name: splinted Implant loading with intra oral welding name: complete denture measure: Assessment of occlusion/disocclusion time sex: ALL minimumAge: 50 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Dentistry Ain Shams University city: Cairo zip: 11361 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06376006 id: 1798538 briefTitle: Evaluating Learning Curves and Competence in Colorectal Endoscopic Mucosal Resection Among Advanced Endoscopy Trainees acronym: EMR-STAT overallStatus: ACTIVE_NOT_RECRUITING date: 2022-05-11 date: 2024-04-01 date: 2024-12-01 date: 2024-04-19 date: 2024-04-24 name: AdventHealth class: OTHER name: Duke University name: University of South Florida name: Stony Brook University name: Atrium Medical Center name: Hofstra University name: Long Island Jewish Medical Center name: Vanderbilt University name: Yale University name: Columbia University name: Geisinger Clinic name: Unity Health Toronto name: University of Virginia name: Baylor University name: University of Kentucky name: Cedars-Sinai Medical Center name: University of Chicago name: University of California, Irvine name: University of Alabama at Birmingham name: Beth Israel Deaconess Medical Center briefSummary: Quality improvement project with the aim to use a standardized assessment tool (EMR-STAT) to establish learning curves and competence thresholds for key cognitive and technical colorectal EMR core skills among advanced endoscopy trainees (AETs). conditions: Competence conditions: Assessment, Self studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 42 type: ESTIMATED name: EMR STAT - Survey measure: Primary Endpoint sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AdventHealth Orlando city: Orlando state: Florida zip: 32804 country: United States lat: 28.53834 lon: -81.37924 hasResults: False
nctId: NCT06375993 id: ADI-202300103 briefTitle: A Phase 1 Study of ADI-001 in Lupus Nephritis overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-12 date: 2027-12 date: 2024-04-19 date: 2024-04-19 name: Adicet Bio, Inc class: INDUSTRY briefSummary: ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion safety/efficacy study in patients with lupus nephritis. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up conditions: Lupus Nephritis conditions: Autoimmune Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: 3+3 Dose Escalation Design primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: ADI-001 name: Fludarabine name: Cyclophosphamide measure: The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort measure: Proportion of treatment emergent and treatment related adverse events sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375980 id: ANKARA_OR_MP briefTitle: Intraoperative Mechanical Power and Ventilation-Associated Lung Injury: Assessing Complications overallStatus: COMPLETED date: 2022-04-01 date: 2022-12-31 date: 2022-12-31 date: 2024-04-19 date: 2024-04-19 name: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital class: OTHER briefSummary: This study investigates the relationship between intraoperative mechanical power and postoperative pulmonary complications in patients undergoing major abdominal surgery. We record mechanical ventilation parameters and surgical characteristics, assessing the incidence of pulmonary complications within 24 hours postoperatively conditions: Lung Injury conditions: Pulmonary Complication studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 207 type: ACTUAL name: Intraoperative Mechanical Ventilation Strategies measure: Relationship between mechanical power and postoperative pulmonary complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Oncology Training and Research Hospital city: Ankara zip: 06200 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06375967 id: CARPEGIEM briefTitle: EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) acronym: CARPEGIEM overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2027-06 date: 2024-04-19 date: 2024-04-19 name: Hospital Universitari de Bellvitge class: OTHER name: Hospital Clínico Universitario de Valencia name: Hospital General Universitario de Alicante name: Hospital Mutua de Terrassa name: Hospital Universitario Ramon y Cajal name: Hospital General Universitario de Castellón name: Complejo Hospitalario de Navarra name: University Hospital Virgen de las Nieves name: Hospital de Sant Pau name: University of Salamanca name: Complejo Hospitalario Universitario de Santiago name: Complejo Hospitalario Universitario de Vigo briefSummary: The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients. conditions: Malignant Biliary Obstruction conditions: Biliary Tract Neoplasms conditions: Pancreatic Cancer Non-resectable studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 128 type: ESTIMATED name: Endoscopic biliary drainage name: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS) name: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS) measure: SAFETY (ADVERSE EVENTS) measure: Recurrent biliary obstruction measure: CLINICAL SUCCESS measure: TECHNICAL SUCCESS measure: BILIARY REINTERVENTIONS (BRI) measure: HOSPITAL STAY measure: MORTALITY measure: COST ANALYSIS sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitari de Bellvitge city: L'Hospitalet De Llobregat state: Barcelona, Catalonia zip: 08907 country: Spain name: Joan B Gornals, PhD role: CONTACT phone: +34 93 260 76 82 phoneExt: 2624 email: jgornals@bellvitgehospital.cat name: Julia Escuer Turu, MD role: CONTACT phone: +34 618 27 28 24 email: jescuer@bellvitgehospital.cat name: Maria Puigcerver Mas, MD role: SUB_INVESTIGATOR name: Sandra Maisterra, MD role: SUB_INVESTIGATOR name: Albert Garcia-Sumalla, MD role: SUB_INVESTIGATOR name: Julio G Velasquez-Rodriguez, MD role: SUB_INVESTIGATOR name: Daniel Luna-Rodriguez, MD role: SUB_INVESTIGATOR name: Carme Loras, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Charly Guarner Argente, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Juan J Vila, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Jose R Aparicio, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Jose Lariño, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Rafa Pedraza, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Antonio Rodriguez D'Jesus, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Alberto Alvarez, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Vicente Sanchiz, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.35967 lon: 2.10028 hasResults: False
nctId: NCT06375954 id: CARPEDIEM-2 briefTitle: EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-06-01 date: 2027-05-01 date: 2024-04-19 date: 2024-04-19 name: Hospital Universitari de Bellvitge class: OTHER name: Hospital Mutua de Terrassa name: Hospital Clínico Universitario de Valencia name: Hospital General Universitario de Alicante name: Hospital Universitario Ramon y Cajal name: Hospital General Universitario de Castellón name: Hospital Álvaro Cunqueiro name: Complejo Hospitalario Universitario de Santiago name: University Hospital Virgen de las Nieves name: Complejo Hospitalario de Navarra name: Hospital de Sant Pau name: University of Salamanca briefSummary: The aim of this clinical trial is to evaluate temporal delay (days) between biliary drainage (EUS-CDS vs ERCP as first line therapy) and chemotherapy start in patients with borderline distal malignant biliary obstruction. conditions: Malignant Biliary Obstruction conditions: Pancreatic Cancer conditions: Biliary Tract Neoplasms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 96 type: ESTIMATED name: Endoscopic biliary drainage name: Self-expandable metallic stent (SEMS) name: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS) measure: Delay in days between endoscopic biliary drainage and chemotherapy treatment start measure: Technical success measure: Clinical success measure: AE - biliary drainage measure: AE - surgery measure: Delay in days between endoscopic biliary drainage and cephalic duodenopancreatectomy (CDP) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitari de Bellvitge city: L'Hospitalet de Llobregat state: Barcelona zip: 08907 country: Spain name: Joan B Gornals, MD, PhD role: CONTACT phone: + 34 93 260 7682 phoneExt: 2624 email: jgornals@bellvitgehospital.cat name: Maria Puigcerver-Mas, MD role: CONTACT phone: +34 687332007 email: mariapuigcervermas@gmail.com name: Julia Escuer, MD role: SUB_INVESTIGATOR name: Sandra Maisterra, MD role: SUB_INVESTIGATOR name: Julio G Velasquez-Rodriguez, MD role: SUB_INVESTIGATOR name: Albert Garcia-Sumalla, MD role: SUB_INVESTIGATOR name: Daniel Luna-Rodriguez, MD role: SUB_INVESTIGATOR name: Berta Laquente, MD, PhD role: SUB_INVESTIGATOR name: Juli Busquets, MD, PhD role: SUB_INVESTIGATOR name: Carme Loras, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Juan J Vila, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Jose Lariño, MD, PhD role: PRINCIPAL_INVESTIGATOR name: VIcente Sanchiz, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Jose R Aparicio, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Eduardo Redondo, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Charly Guarner-Argente, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Antonio Rodriguez D'Jesus, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Alberto Alvarez, MD, pHD role: PRINCIPAL_INVESTIGATOR lat: 41.35967 lon: 2.10028 hasResults: False
nctId: NCT06375941 id: ProStars briefTitle: Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars acronym: ProStars overallStatus: RECRUITING date: 2024-03-29 date: 2029-04-01 date: 2034-04-01 date: 2024-04-19 date: 2024-04-19 name: Italian Sarcoma Group class: NETWORK briefSummary: This study will be a multi-institutional, prospective, observational study of patients with localized primary AS of any site within ISG and RTR centers. Patients will be treated according to clinical practice of the center and according to ISG clinical recommendations on localized AS. conditions: Angiosarcoma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 250 type: ESTIMATED name: Observational measure: Demographic characteristics measure: General characteristics measure: Cancer data measure: Origin of Tumor measure: Tumor characteristics measure: Tumor size measure: Tumor aspects measure: Pathological characteristics measure: Tumor phenotype measure: Molecular characteristics sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituto Nazionale Tumori - Milano status: RECRUITING city: Milano zip: 20133 country: Italy name: Palassini Elena role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False